Seung-Won Jung

Dr. Seung-Won Jung

Wonju Severance Christian Hospital, Wŏnju, Gangwon, Republic of Korea
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
Seung-Won JungSeung-Won Jung
Seung-Won Jung
JJJae Joon Jeon
Jae Joon Jeon
YKYou Hyun Kim
You Hyun Kim
SCSung Jay Choe
Sung Jay Choe
SLSolam Lee
Solam Lee
The long-term association between mRNA-based coronavirus disease 2019 (COVID-19) vaccination and the development of autoimmune connective tissue diseases (AI-CTDs) remains unclear. In this nationwide, population-based cohort study involving 9,258,803 individuals, we aim to determine whether the incidence of AI-CTDs is associated with mRNA vaccination. The study spans over 1 year of observation and further analyses the risk of AI-CTDs by stratifying demographics and vaccination profiles and treating booster vaccination as time-varying covariate. We report that the risk of developing most AI-CTDs did not increase following mRNA vaccination, except for systemic lupus erythematosus with a 1.16-fold risk in vaccinated individuals relative to controls. Comparable results were reported in the stratified analyses for age, sex, mRNA vaccine type, and prior history of non-mRNA vaccination. However, a booster vaccination was associated with an increased risk of some AI-CTDs including alopecia areata, psoriasis, and rheumatoid arthritis. Overall, we conclude that mRNA-based vaccinations are not associated with an increased risk of most AI-CTDs, although further research is needed regarding its potential association with certain conditions.

Verified
Journal Article
Open access
PDF file
Seung-Won JungSeung-Won Jung
Seung-Won Jung
GPGihyun Park
Gihyun Park
EKEunjung Kim
Eunjung Kim
KYKang Min Yoo
Kang Min Yoo
HKHea Won Kim
Hea Won Kim
ECEung Ho Choi
Eung Ho Choi
Stratum corneum (SC) pH regulates skin barrier functions and elevated SC pH is an important factor in various inflammatory skin diseases. Acidic topical formulas have emerged as treatments for impaired skin barriers. Sodium proton exchanger 1 (NHE1) is an important factor in SC acidification. We investigated whether topical applications containing an NHE1 activator could improve skin barrier functions. We screened plant extracts to identify NHE1 activators in vitro and found Melissa officinalis leaf extract. Rosmarinic acid, a component of Melissa officinalis leaf extract, significantly increased NHE1 mRNA expression levels and NHE1 production. Immunofluorescence staining of NHE1 in 3D-cultured skin revealed greater upregulation of NHE1 expression by NHE1 activator cream, compared to vehicle cream. Epidermal lipid analysis revealed that the ceramide level was significantly higher upon application of the NHE1 activator cream on 3D-cultured skin, compared to application of a vehicle cream. In a clinical study of 50–60-year-old adult females (n = 21), application of the NHE1 activator-containing cream significantly improved skin barrier functions by reducing skin surface pH and transepidermal water loss and increasing skin hydration, compared to patients who applied vehicle cream and those receiving no treatment. Thus, creams containing NHE1 activators, such as rosmarinic acid, could help maintain or recover skin barrier functions.

3 May 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
Seung-Won JungSeung-Won Jung
Seung-Won Jung
SLSung Ha Lim
Sung Ha Lim
JJJae Joon Jeon
Jae Joon Jeon
YHYeon-Woo Heo
Yeon-Woo Heo
MCMi Soo Choi
Mi Soo Choi
Seung-Phil HongSeung-Phil Hong
Seung-Phil Hong
Biologics are important treatment options for psoriasis; however, direct comparison of their efficacy, safety, and drug survival is insufficient in clinical practice. This retrospective single-center study aimed to compare the efficacy, safety, and drug survival of three commonly used psoriasis biologics (secukinumab, ustekinumab, and guselkumab) and identify the factors affecting drug survival in actual clinics in Korea. We enrolled 111 patients with moderate to severe psoriasis and for at least 56 weeks of follow-up; among these, 27, 23, and 61 were administered secukinumab, ustekinumab, and guselkumab, respectively. All groups were comparable with respect to their baseline characteristics. Secukinumab showed a rapid response, and guselkumab was superior in terms of a long-term response and complete remission compared with other biologics, while ustekinumab showed a lower efficacy compared with other biologics. All three biologics had a favorable and similar safety profile; however, allergic reactions and latent tuberculosis were more common with secukinumab and ustekinumab, respectively. Guselkumab was the most sustained biologic, and the survival rates of secukinumab and ustekinumab were similar. Drug survival was remarkably shorter in female patients and those with hypertension. Introduction of new biologics emerged as a negative factor for drug survival in clinical settings.

1 January 2025 in Annals of Dermatology
Verified
Journal Article
Open access
PDF file
Seung-Won JungSeung-Won Jung
Seung-Won Jung
LPLong-Quan Pi
Long-Quan Pi
JJJae Joon Jeon
Jae Joon Jeon
YKYou Hyun Kim
You Hyun Kim
SLSolam Lee
Solam Lee
WLWon-Soo Lee
Won-Soo Lee
Jung SW, et al. Ann Dermatol. 2024 Oct;36:e64. https://doi.org/10.5021/ad.24.047

11 December 2022 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
Seung-Won JungSeung-Won Jung
Seung-Won Jung
SLSolam Lee
Solam Lee

1 January 2024 in Annals of Dermatology
Verified
Journal Article
Open access
PDF file
SLSang-Hoon Lee
Sang-Hoon Lee
Seung-Won JungSeung-Won Jung
Seung-Won Jung
WLWon-Soo Lee
Won-Soo Lee
Lee SH, et al. Ann Dermatol. 2024 Jun;36(3):188-190. https://doi.org/10.5021/ad.23.032